Skip to main content
OpenTrials

Clinical trial condition

Lung Cancer, Non-small Cell

Explore clinical trials studying Lung Cancer, Non-small Cell. Study availability and eligibility vary by location and protocol.

44 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Lung Cancer, Non-small Cell trial results

Completed

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

NCT01362296

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Orange, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Jacksonville, Florida, United States
View all 60 locations
View Trial Details
Completed

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

NCT00390806

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Glendale, Arizona, United States
  • GSK Investigational Site Hot Springs, Arkansas, United States
  • GSK Investigational Site Anaheim, California, United States
View all 88 locations
View Trial Details
Completed

Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer

NCT00367679

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • GSK Investigational Site Duarte, California, United States
  • GSK Investigational Site Rancho Mirage, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Newark, Delaware, United States
View Trial Details
Active, Not Recruiting

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Ocala, Florida, United States
  • GSK Investigational Site Honolulu, Hawaii, United States
  • GSK Investigational Site Lexington, Kentucky, United States
  • GSK Investigational Site Lexington, Kentucky, United States
View all 108 locations
View Trial Details
Active, Not Recruiting

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Walnut Creek, California, United States
  • GSK Investigational Site Norwich, Connecticut, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
View all 163 locations
View Trial Details
Active, Not Recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Plantation, Florida, United States
  • GSK Investigational Site Albuquerque, New Mexico, United States
  • GSK Investigational Site Chattanooga, Tennessee, United States
  • GSK Investigational Site Morgantown, West Virginia, United States
View all 99 locations
View Trial Details

Related conditions